Clinical Trial

A Clinical Trial Evaluating TQF3250 Capsules in Healthy Adult Subjects

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
TQF3250 capsule is a biased GLP-1 (glucagon-like peptide-1) receptor agonist developed by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. By binding to the GLP-1 receptor, it can selectively activate certain signaling pathways of the GLP-1 receptor and reduce activation of other pathways, thereby bringing higher efficacy and lower side effects.
Trial Details
NCT Number NCT07327281
Lead Sponsor Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions Hyperglycemia
Enrollment 66 participants
Start Date 2025-12-18
Primary Completion 2026-12 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-01-08